Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaMedica has reported positive preclinical data for DM-99, its third clinical drug candidate. Results demonstrated, with statistical significance, greater glucose metabolism in normal animals treated with DM-99 when compared to untreated animals.
Subscribe to our email newsletter
In the study, the amount of glucose being metabolized was measured using the well established hyperinsulinemic euglycemic clamp model. Specifically, animals treated with DM-99 were able to use 41% more glucose than an untreated animal (p less than 0.04) during the first 60 minutes of the study.
Karl-Gunnar Hidinger, president of DiaMedica, said: “Based upon the collective results of our preclinical studies, we have already initiated the regulatory clearance process for a Phase II human study with DM-99 and expect to receive feedback in the near term. We plan to test DM-99 as a stand-alone therapy in a meal-tolerance model.”